A unique disease known as amyotrophic lateral sclerosis (ALS) and Parkinsonism Dementia Complex (PDC) or ALS/PDC is observed in the Chamorro people of Guam. The clinical features of ALS observed are similar if not identical to ALS observed in other parts of the world. However, Guam ALS is neuropathologically unique in that neurofibfillary tangles, are observed in the cortex and spinal cord, a finding atypical of classical ALS. PDC is Parkinsonism features observed with dementia; again, the neuropathologic features, which are essentially identical to Guam ALS, distinguish PDC from Parkinson's disease. Guam ALS and PDC are considered different clinical manifestations of the same disease. Guam dementia is another disease entity that is clinically indistinguishable from Alzheimer's disease (AD) and may be an additional form of ALS/PDC. Clustering of ALS/PDC in families and a high incidence in specific villages on Guam indicates that genetic factors are important in disease susceptibility. Also, the increase in age-of-onset of ALS and PDC, and the decrease in the incidence of ALS indicate that environmental factors, possibly unique to Guam, are also involved. The goal of this proposal is to identify the genetic susceptibility factors involved in ALS/PDC. Previous work indicated that tau is a susceptibility factor for ALS/PDC but is not the major gene responsible for this group of diseases. This proposal will focus on: 1) identifying additional susceptibility factors for ALS/PDC; 2) identifying the tau alleles the confer susceptibility to ALS/PDC; 3) characterize Guam dementia in terms of genetic markers for AD such as ApoE promoter polymorphisms and ALS/PDC such as tau.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
2P01AG014382-06
Application #
6481383
Study Section
Special Emphasis Panel (ZAG1-FAS-7 (J4))
Project Start
1997-03-01
Project End
2007-03-31
Budget Start
Budget End
Support Year
6
Fiscal Year
2002
Total Cost
$287,319
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Dombroski, Beth A; Galasko, Douglas R; Mata, Ignacio F et al. (2013) C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex. JAMA Neurol 70:742-5
Brunden, Kurt R; Ballatore, Carlo; Lee, Virginia M-Y et al. (2012) Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans 40:661-6
Lee, Virginia M-Y; Brunden, Kurt R; Hutton, Michael et al. (2011) Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med 1:a006437
Yu, Chang-En; Bird, Thomas D; Bekris, Lynn M et al. (2010) The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol 67:161-70
Brunden, Kurt R; Ballatore, Carlo; Crowe, Alex et al. (2010) Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol 223:304-10
Snyder, L R; Cruz-Aguado, R; Sadilek, M et al. (2009) Lack of cerebral bmaa in human cerebral cortex. Neurology 72:1360-1
Choi, Yoonha; Wijsman, Ellen M; Weir, Bruce S (2009) Case-control association testing in the presence of unknown relationships. Genet Epidemiol 33:668-78
Sieh, Weiva; Choi, Yoonha; Chapman, Nicola H et al. (2009) Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates. Hum Mol Genet 18:3725-38
Crowe, Alex; Huang, Wenwei; Ballatore, Carlo et al. (2009) Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48:7732-45
Brunden, Kurt R; Trojanowski, John Q; Lee, Virginia M-Y (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8:783-93

Showing the most recent 10 out of 53 publications